Subconjunctival Bevacizumab and Recurrent Pterygium

Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01744756

Acronym

BRP

Enrollment

Registered

2012-12-07

Start date

2012-02-29

Completion date

2012-09-30

Last updated

2012-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pterygium

Keywords

Subconjunctival Bevacizumab, Recurrent pterygium

Brief summary

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Detailed description

1. Pacients with recurrent pterygium 2. Anti-VEGF therapy -Bevacizumab

Interventions

DRUGBevacizumab

One subconjunctival aplication of Bevacizumabe 0,5ml

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Recurrent pterygium

Exclusion criteria

* Pregnant or lactating women * History of myocardial infarction * History of stroke

Design outcomes

Primary

Measure	Time frame	Description
Pterygium size after subconjunctival bevacizumab	8 weeks	-Size of recurrent pterygium (measured in mm) after injection

Secondary

Measure	Time frame	Description
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	8 weeks	-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026